An interventional study of Turmeric in Epilepsy, Dravet Syndrome and Lennox-Gastaut Syndrome, sponsored by NYU Langone Health. Withdrawn at 1 site in United States. Open to participants aged 1 Year to 70 Years. Per ClinicalTrials.gov, last updated 2018-04-30.
Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment
Among 24 studies in Epilepsy by NYU Langone Health — 5 open to participants now, 6 under way, none of them phase 3. Epilepsy · NYU Langone Health.
Among the 24 studies in Epilepsy by NYU Langone Health, this one is the 17th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2018, is one of 16 with no phase, and was the 20th registered.
1,848 studies on the registry are indexed under Epilepsy; 422 are open to participants now.
Browse Epilepsy studies →5 of the 24 studies in Epilepsy by NYU Langone Health are open now, in 1 country. Each count lists the studies.
Of the 285 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 149 (52%) stop at 75 or younger; 139 take children under 18; 56 take healthy volunteers.
This study: 1 Year to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →24 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2018.
Median enrollment 15 across the 21 interventional studies, 488 across the 3 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
NYU Langone Health is the lead sponsor of 1,430 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
4 of the studies in Epilepsy by NYU Langone Health that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03233399NYU Langone HealthModulating Movement Intention Via Cortical Stimulation | 2027-05 |
| NCT05082181NYU Langone HealthTelephone-Based Support Programs for People With Epilepsy | 2027-08-31 |
| NCT01662453NYU Langone HealthRisk Factors for Sudden Unexplained Death in Epilepsy | 2027-09 |
| NCT07087821NYU Langone HealthNYU Epilepsy Self-Management Study | 2027-09-29 |
Among the 24 studies in Epilepsy by NYU Langone Health, from their registry updates:
Nothing recorded among them since 2026-09-25.
This is a single center open-label pilot clinical trial of patients 1-70 years of age with greater than 6 seizures per month diagnosed with Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis, or focal seizures. Twenty patients will be enrolled and treated with a stable dose of orally administered turmeric oil daily for 3 months. Patients and caregivers will be asked to keep a seizure diary logging all clinical events during the course of the study. Serum comprehensive metabolic panel, complete blood count with differential, and antiseizure medication levels, will be monitored at baseline, 1.5 months, and at the end of 3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
stable dose of orally administered turmeric oil
Dietary Supplement: Turmeric
Drug pages: Turmeric extract · Curcuma longa
Twenty patients will be enrolled and treated with a stable dose of orally administered turmeric oil daily for 3 months.
Number of epilepsy patients enrolled in study
feasibility of recruiting patients into a prospective study designed to evaluate the effect of orally ingested turmeric oil on seizures.
Time frame: 3 months
Number of epilepsy seizures post epilepsy treatment with turmeric
Time frame: 3 months
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Mar 2018; primary completion for Nov 2018, 8 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Turmeric extract · Curcuma longa